Prenetics Global Limited, a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, announced the appointment of Dr Darshan Shah as an independent director to its Board of Directors, effective February 16, 2026. Dr Shah will also serve as a member of the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.
Dr Shah is a board-certified surgeon and a recognised expert in longevity medicine with over 20 years of experience in clinical practice and healthcare entrepreneurship. Most recently, Dr Shah gained national recognition as the medical expert and formulator of Liquid Death's new energy drink, featured in a Super Bowl LX advertisement on February 6, 2026. This high-profile collaboration, combined with his experience building and scaling Next Health into one of the world's premier longevity centres, brings a unique combination of high-level medical science and proven mass-market product formulation expertise to Prenetics’ Board.
"Dr Shah's appointment is a strategic move that significantly enhances the scientific and commercial expertise of our Board," said Danny Yeung, Chairman and CEO of Prenetics. "It is exceptionally rare to find someone with both the depth of medical expertise of Mayo Clinic-trained, 20,000+ surgeries, and the entrepreneurial track record of building and scaling a national health brand. His unique journey, from the Mayo Clinic to the Super Bowl, is a perfect fit for our mission to build a world-class health and longevity brand with IM8. We are confident that his deep expertise in clinical trials, product formulation, and building world-class health brands will be instrumental in driving innovation and creating long-term shareholder value."
Dr Shah said, “I am thrilled to join the Prenetics Board at such an inflection point. Having gotten to know Danny and the team over the past six months, I have been highly impressed with his vision and the Company’s commitment to science. Prenetics’ serious investment in upcoming clinical trials and data-driven product development is a mission I deeply share. Having built products and brands at the intersection of clinical science and consumer appeal, I understand the unique challenges and opportunities Prenetics faces as it scales IM8 globally, and I look forward to contributing my experience to help guide that next phase of growth.”
